GENES EXPRESSED IN BREAST CANCER AS PROGNOSTIC AND THERAPEUTIC TARGETS

Details for Australian Patent Application No. 2002307241 (hide)

Owner NOVARTIS AG

Inventors DRESSMAN, Marlene, Michelle; LAVEDAN, Christian, Nicolas; POLYMEROPOULOS, Mihael

Pub. Number AU-A-2002307241

PCT Number PCT/US02/11313

PCT Pub. Number WO2002/092854

Priority 60/291,428 16.05.01 US

Filing date 11 April 2002

Wipo publication date 25 November 2002

International Classifications

C12Q 001/68 Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

C12N 015/86 Mutation or genetic engineering - Viral vectors

Event Publications

19 December 2002 Complete Application Filed

  Priority application(s): 60/291,428 16.05.01 US

1 May 2003 Application Open to Public Inspection

  Published as AU-A-2002307241

4 March 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002307242-Improved medical instrument flow stop interface

2002307240-Coated article with polymeric basecoat having a stainless steel color